Inflammation-related biomarkers as predictors of pathological complete response in early-stage breast cancer

期刊论文
发表日期：

2024年12月12日

查看全文

Oraianthi Fiste,
Evangelos Mavrothalassitis,
Alexandros Kokkalis,
Maximilian Anagnostakis,
Georgia Gomatou,
Athanasios Kontogiannis,
Dimitra Karaviti,
Eleftheria Karaviti,
Nikolaos Konstantinos Syrigos,
Athanasios Kotsakis,
Elias Alexandros Kotteas

摘要

Background

Neoadjuvant systemic therapy (NAT) represents an attractive option for improved outcomes of early-stage breast cancer (BC) patients, as it can significantly reduce tumor burden thus permitting breast-conserving resections. Equally important, the eradication of viable cancer cells post-NAT, also known as pathological complete response (pCR), has emerged as a strong prognostic biomarker, reflecting tumor’s biology and subsequent treatment responses. Yet to date, no validated markers predictive of pCR have been identified.

Methods

The present retrospective study aimed to explore the value of neutrophil-tolymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as potential predictors of pCR.

Results

Despite no statistically significant associations have been reported, NLR and PLR dynamics during NAT, as longitudinal inflammatory phenotypes, merit further investigation in larger cohorts.

Conclusion

In the future, the integration of a comprehensive inflammatory biomarker panel into clinical practice could assist in a priori treatment selection process.